Generium’s Elizaria: First Biosimilar to Eculizumab

Generium launches the first biosimilar drug to eculizumab, known as Elizaria. What is a biosimilar? What might this biosimilar mean for aHUS patients, and the physicians who treat them? The aHUS Alliance looks at the science behind biosimilars, as well as issues such as drug cost and access for those affected by the rare disease atypical HUS.

Continue ReadingGenerium’s Elizaria: First Biosimilar to Eculizumab

OMS721: Omeros Research Collaboration with University of Cambridge

Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?

Continue ReadingOMS721: Omeros Research Collaboration with University of Cambridge

Breaking Down Barriers in aHUS Clinical Trials

Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.

Continue ReadingBreaking Down Barriers in aHUS Clinical Trials

South African Pediatric Nephrology: Global Panel Proposed for aHUS Drug Access

Dr Errol Gottlich  and  Professor Mignon McCulloch   ¬†Resilience, fortitude and determination. These characteristics describe the South African doctor treating patients within a complex and changing…

Continue ReadingSouth African Pediatric Nephrology: Global Panel Proposed for aHUS Drug Access